Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB053914 with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT04355039Phase 1Withdrawn
- Sponsor
- Medical College of Wisconsin
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of INCB053914 in multiple myeloma (MM) (3 cohorts), sponsored by Medical College of Wisconsin. Primary endpoint: Dose-Limiting Toxicities at 28 days. Planned start Jul 2021; status: withdrawn.
02
Drugs
INCB053914
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04355039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04355039.